Hypertension News

This section informs healthcare professionals of the latest medical information via daily news articles on hypertension and other related areas.

Recent Headlines

• High Blood Pressure Increases Risk Of Dementia By Up To 600 Per Cent

  Tuesday, July 8, 2008
  People with high blood pressure are up to six hundred per cent more likely to develop dementia according to new research, released by Alzheimer's Society during Dementia Awareness Week (6- 12 July 2008). High blood pressure led to a six fold increase in vascular dementia, the second most common form of dementia in the UK, according to the research.

• Boehringer Ingelheim Launches New Powerful Blood Pressure Treatment, MicardisPlus 80/25mg (telmisartan/hydrochlorothiazide), In The UK

  Tuesday, July 8, 2008
  Boehringer Ingelheim announced that a new formulation of its powerful blood pressure lowering drug, telmisartan (Micardis®) with hydrochlorothiazide (HCTZ), is now available in the UK. The fixed dose combination of 80mg telmisartan and 25mg HCTZ, which will be marketed as MicardisPlus® 80/25mg, is licensed for the treatment of essential hypertension in people whose blood pressure is not adequately controlled on 80mg telmisartan/12.

• Men, Blacks In Particular, Less Likely Than Women To Be Aware That They Have High Blood Pressure, Study Finds

  Friday, July 4, 2008
  Men are one-quarter less likely than women to know that they have high blood pressure and black men with high blood pressure, are particularly unlikely to know of their condition, according to study published in the Archives of Internal Medicine, Reuters Health reports. For the study, lead researcher Ronald Victor of the University of Texas'

• The Underlying Molecular Mechanism For Hypertension, Insulin Resistance And Other Metabolic Complications Identified

  Tuesday, July 1, 2008
  Many of the 75 million Americans with essential hypertension also develop diabetes and other complications in addition to their high blood pressure, and researchers have discovered a common molecular mechanism in a strain of rat that explains why such metabolic disorders arise together in mammals.

• AstraZeneca Submits For New Dosage Strengths Of Atacand Plus - New Dosing Regimen Offers Patients Greater Chance To Reach Target Blood Pressure

  Tuesday, July 1, 2008
  AstraZeneca announced a European decentralized procedure (DCP) submission seeking approval for two new dose strengths of Atacand Plus, for those hypertensive patients not optimally controlled by monotherapy. The reference member state for the procedure is Sweden, and the submission incorporates data from three studies. 1,2,3 The new strengths of the fixed dose combination Atacand Plus, comprised of candesartan cilexetil and hydrochlorothiazide (HCT) in doses of 32/12.

• New Drug Application For Inhaled Treprostinil Submitted To The U.S. Food And Drug Administration

  Tuesday, July 1, 2008
  United Therapeutics Corporation (Nasdaq: UTHR) and its wholly-owned subsidiary, Lung Rx, Inc., announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for marketing approval of an inhaled formulation of treprostinil (ITRE) for the treatment of pulmonary arterial hypertension (PAH), a chronic, life-threatening disease. The submission starts a 60-day period during which the FDA will examine the application for completeness.

• Men, Especially Blacks, More Likely To Miss Own Hypertension

  Friday, June 27, 2008
  A new study suggests that American men are much more likely than women are to be unaware that they suffer from high blood pressure. African-American men with the condition are at the highest risk, with only one in seven both aware of their illness and able to control it through medication.

• Hard Work While Fatigued Affects Blood Pressure

  Friday, June 27, 2008
  Working hard when fatigued may be admired by many Americans, but it is a virtue that could be harmful to one's health, according to new research by psychologists at the University of Alabama at Birmingham (UAB). The research supports a theory which suggests that exhausted individuals' cardiovascular systems are forced to work harder when they attempt to complete tasks, such as those encountered on the job or at school.

• Hypertension Predicted By High Levels Of Urinary Albumin In The Normal Range

  Friday, June 27, 2008
  Healthy individuals with higher levels of albumin excretion, even levels considered normal, are at increased risk of developing hypertension (high blood pressure), according to a study appearing in the October 2008 issue of the Journal of the American Society Nephrology (JASN). The study suggests that to prevent cardiovascular disease, the definition of "normal" urinary albumin excretion should be reconsidered.

• Start Of Phase 2a Clinical Study Of Angiotensin Therapeutic Vaccine In Hypertension

  Thursday, June 26, 2008
  Protherics PLC "Protherics" or the "Company"), the international biopharmaceutical company focused on critical care and cancer, today announces that the first patient has been enrolled in a phase 2a study of its Angiotensin Therapeutic Vaccine (ATV) for the treatment of hypertension.

• Micardis®-based Regimens Help More Patients Achieve Their Blood Pressure Goals

  Tuesday, June 24, 2008
  The results of two new studies of Micardis® (telmisartan) in free combination with amlodipine or fixed combination with hydrochlorothiazide (HCTZ) 25 mg confirm that a telmisartan-based approach to treating hypertensive patients at risk of cardiovascular events can provide powerful and sustained blood pressure control in a broad range of people, including those who are difficult-to-treat.

• Management Of High Blood Pressure Immediately After Stroke

  Tuesday, June 24, 2008
  A research project at the University of Leicester in conjunction with the University of East Anglia, indicates that early reduction of high blood pressure following stroke is feasible and safe, and both Labetalol & Lisinopril were found to be suitable a medications for this purpose. Larger studies will now be necessary to confirm this result and test the effects on recovery from stroke.

• Pfizer And Ranbaxy Settle Lipitor Patent Litigation Worldwide

  Monday, June 23, 2008
  Pfizer Inc announced that it has entered into an agreement with generics manufacturer Ranbaxy Laboratories Ltd. of India and certain of its affiliates to settle substantially all their patent litigation worldwide involving Lipitor, the world's most-prescribed cholesterol-lowering medicine. Under the terms of the agreement, Ranbaxy will have a license to sell generic versions of Lipitor and Caduet in the United States effective November 30, 2011.

• Insomnia Linked To High Blood Pressure

  Saturday, June 21, 2008
  Insomniacs who sleep fewer than five hours a night are five times more likely to suffer hypertension than people who sleep well, according to a major study that highlights the growing concerns over links between sleep problems and serious illness.

• Controlling Perioperative Hypertension With Cleviprex Reduces Heart Attack And Death RIsk Following Cardiac Surgery, According To New Analyses

  Saturday, June 21, 2008
  The Medicines Company (NASDAQ: MDCO) today announced that data from two post-hoc analyses of the ECLIPSE trial showed that use of Cleviprex™ (clevidipine butyrate) injectable emulsion to control blood pressure during cardiac surgery may be associated with a reduced risk of heart attack compared to two of three currently used IV antihypertensive agents. In a separate sub-analysis, Cleviprex was associated with a lower 30-day mortality compared to two nitrovasodilators.

• Controling Risk Factors Reduces Risk Of Stroke By 42 Percent

  Saturday, June 21, 2008
  Results of a new analysis of the Treating to New Targets (TNT) study show that intensive low-density lipoprotein (LDL) cholesterol-lowering in patients with stable coronary heart disease (CHD) whose systolic blood pressure was less than 140 mmHg reduced the risk of major cardiovascular events, including heart attack, stroke and resuscitated cardiac arrest, by 42 percent compared with less intensive LDL lowering and uncontrolled blood pressure of 140 mmHg or higher. Led by John B.

• High Blood Pressure In Childhood Usually Continues Into Adulthood

  Thursday, June 19, 2008
  US researchers reviewing published studies covering up to forty years found that children with high blood pressure usually continue to have high blood pressure as adults. The research was the work of senior author Dr Youfa Wang and colleague Dr Xiaoli Chen from the Johns Hopkins Bloomberg School of Public Health in Baltimore, Maryland and is published online in the June 2008 issue of the journal Circulation.

• Two-Year Clinical Trial Findings Show Significant And Persistent Reduction In Blood Pressure With CVRx(R) Rheos(R) Hypertension Therapy

  Thursday, June 19, 2008
  The first available two-year data from the European clinical trial evaluating the Rheos® Hypertension (HT) System were presented at Hypertension Berlin 2008. Developed by U.S.-based CVRx, Inc., the Rheos HT System is the only implantable medical device designed to control hypertension, or high blood pressure. Worldwide, hypertension is a leading and growing cause of heart and kidney disease, stroke and death.

• Vascular Damage Effectively Reversed Using Hypertension Treatment

  Wednesday, June 18, 2008
  A hypertension medication called olmesartan medoxomil is effective in reversing the narrowing of the arteries that occurs in patients with high blood pressure, according to a new study. Carlos M. Ferrario, M.D.

• Blood Pressure Levels In Childhood Track Into Adulthood

  Tuesday, June 17, 2008
  High blood pressure in childhood is associated with higher blood pressure or hypertension in adulthood, according to a study by researchers at the Johns Hopkins Bloomberg School of Public Health. Their analyses of previously published blood pressure tracking studies over the last four decades show a consistent relationship between children's blood pressure levels with their blood pressure levels as adults.

• Blood Pressure Lowering Effect Of Hypertension Treatment Device Further Validated In New Studies

  Tuesday, June 17, 2008
  European Society of Hypertension -- Booth # 21, Hall 15.1 -- InterCure Ltd., a medical device company publicly traded on the Tel-Aviv Stock Exchange (TASE: INCR), announced the findings of new studies and analysis highlighting RESPeRATE -- the only medical device cleared by the FDA and CE-approved for the treatment of hypertension. Five posters will be presented at the European Society of Hypertension meeting (ESH) in Berlin beginning June 14, 2008.

• New Study Shows BENICAR(R) (olmesartan Medoxomil) Reverses Blood Vessel Damage Independent Of Blood Pressure Lowering

  Tuesday, June 17, 2008
  A new study published in the current Journal of the American Society of Hypertension demonstrates that the hypertension treatment olmesartan medoxomil was effective in reversing the narrowing of the arteries that occurs in patients with hypertension. The study, titled VIOS (Vascular Improvement with Olmesartan medoxomil Study) was a one-year, exploratory study that evaluated the effects of an angiotensin receptor blocker (olmesartan medoxomil) vs.

• Teva Announces Tentative Approval Of Generic Diovan(R) Tablets

  Sunday, June 15, 2008
  Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced that the U.S. Food and Drug Administration has granted tentative approval for the Company's Abbreviated New Drug Application (ANDA) to market its generic version of Novartis' hypertension treatment Diovan® (Valsartan) Tablets, 40 mg, 80 mg, 160 mg and 320 mg.

• Serum Sodium Predicts Mortality Ten Times Higher In PAH Patient

  Saturday, June 14, 2008
  Patients with pulmonary arterial hypertension (PAH) chronically high blood pressure in the blood vessels of the lungs whose serum sodium levels are low (called hyponatremia, or HN) have a very poor chance of survival and a high rate of right-heart failure (RHF), according to new research from the University of Pennsylvania.

• NicOx Announces Blood Pressure Analysis From 301 Phase 3 Study For Naproxcinod At EULAR

  Saturday, June 14, 2008
  NicOx S.A. (Euronext Paris: COX) announced an additional analysis of the blood pressure data from the 301 phase 3 study, showing a statistically significant difference between naproxcinod and naproxen in terms of the mean change from baseline in systolic and diastolic blood pressure at week 13 (p